-
Patent Agency Ranking
公开(公告)号：US20170231999A1
公开(公告)日：2017-08-17
申请号：US15584818
申请日：2017-05-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: A61K31/538 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K39/395 , A61K45/06
CPC classification number: C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US09675571B2
公开(公告)日：2017-06-13
申请号：US14776035
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Bin Chen , Libing Chen , Steven P. Seitz , Amy C. Hart , Jay A. Markwalder
IPC: A61K31/135 , A61K31/196 , C07C255/44 , C07C255/57 , C07D213/84 , C07C275/42 , C07D317/66 , C07C311/51 , C07D239/42 , C07D241/42 , C07D257/04 , C07D261/08 , C07C233/55 , C07D261/14 , C07C235/38 , C07D271/12 , C07D213/56 , A61K31/18 , A61K31/216 , A61K31/27 , A61K31/36 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/44 , A61K31/498 , A61K31/505 , A61K45/06 , A61N5/10 , C07C69/743 , C07C271/28 , C07C311/47 , C07D213/75
CPC classification number: A61K31/196 , A61K31/18 , A61K31/216 , A61K31/27 , A61K31/36 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/44 , A61K31/498 , A61K31/505 , A61K45/06 , A61N5/10 , C07B2200/07 , C07C69/743 , C07C233/55 , C07C235/38 , C07C255/44 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/47 , C07C311/51 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/02 , C07C2602/08 , C07C2602/14 , C07C2602/42 , C07D213/56 , C07D213/75 , C07D213/84 , C07D239/42 , C07D241/42 , C07D257/04 , C07D261/08 , C07D261/14 , C07D271/12 , C07D317/66 , Y02A50/411 , Y02A50/414
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US09598436B2
公开(公告)日：2017-03-21
申请号：US14968259
申请日：2015-12-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang
IPC: C07D413/00 , C07D498/04 , C07D413/14 , C07D409/04 , C07D413/04 , C07D487/04 , C07D409/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D519/00 , C07D413/06
CPC classification number: C07D498/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00
Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
-
公开(公告)号：US08969586B2
公开(公告)日：2015-03-03
申请号：US14347893
申请日：2012-09-27
Applicant: Bristol-Myers Squibb Company
Inventor： James Aaron Balog , Audris Huang
IPC: C07D413/00 , C07D413/06 , C07D498/04 , C07D413/14 , C07D409/04 , C07D413/04 , C07D487/04 , C07D409/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D519/00
CPC classification number: C07D498/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00
Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
Abstract translation: 公开了式（I）的氮杂吲唑化合物或其药学上可接受的盐，其中：X为O且Y为N; 或X为S，Y为CH; Z是CR2或N; Q是杂芳基; 并且R1在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。
-
公开(公告)号：US20140235647A1
公开(公告)日：2014-08-21
申请号：US14347893
申请日：2012-09-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Audris Huang , Upender Velaparthi , Peiying Liu
IPC: C07D487/04 , C07D417/14 , C07D413/14 , C07D413/06 , C07D471/04
CPC classification number: C07D498/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00
Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
Abstract translation: 公开了式（I）的氮杂吲唑化合物或其药学上可接受的盐，其中：X为O且Y为N; 或X为S，Y为CH; Z是CR2或N; Q是杂芳基; 并且R1在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。
-
-
-
-
Search Results
35
records
(took 0.055 seconds)
